News | March 13, 2015

First Two Patients Enrolled and Treated in AtriCure’s Landmark Afib Study

Study teams cardiac surgeons and electrophysiologists to perform both surgical and catheter ablation

March 13, 2015 — AtriCure Inc. announced the first two patients in the Dual Epicardial and Endocardial Procedure (DEEP) clinical study have been enrolled and treated at PinnacleHealth CardioVascular Institute in Harrisburg, Pennsylvania. The study is the first of its kind in the United States for the treatment of persistent or longstanding persistent forms of atrial fibrillation (Afib).

In the DEEP study, cardiac surgeons and electrophysiologists work as a team to perform a minimally invasive epicardial (outside the heart) surgical ablation and endocardial (inside the heart) catheter-based ablation. The primary effectiveness endpoint of the study is freedom from Afib and absence of Class I or III antiarrhythmic drug therapy. AtriCure received approval in November 2014 from the U.S. Food and Drug Administration to enroll 220 patients at 25 sites in the DEEP study.

Atrial fibrillation patients who have failed anti-arrhythmic drug therapy and may have received up to two failed catheter ablations are candidates for the DEEP study, which is performed in two phases. In the first phase, the surgeon will make small incisions to perform endoscopic epicardial ablation using the AtriCure Bipolar System, and exclude the left atrial appendage (LAA) with the AtriClip LAA Exclusion System.

The first procedure in the study was performed by Mubashir Mumtaz, M.D., chief of cardiovascular and thoracic surgery at PinnacleHealth.

"We feel privileged to be part of this landmark study in our quest to find a safe and reliable treatment for millions of people affected by atrial fibrillation,” said Mumtaz. “We really believe that this trial will provide much needed insight into this disease. We are excited and feel honored to be able to enroll and treat the first two patients to kick off the trial."

The second phase of the procedure, catheter ablation and endocardial mapping, will be performed by Michael G. Link, M.D., electrophysiologist at PinnacleHealth, about 90 to 120 days after the surgical procedure.

“I am excited about DEEP because the more persistent forms of atrial fibrillation have been historically difficult to treat, with disappointing results,” said Link. “I am honored to be at the forefront of this trial which will hopefully alter the standard of care for these patients."

For more information:

Related Content

Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Clinical Study | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Clinical Study | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Clinical Study | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Clinical Study | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Clinical Study | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init